» Articles » PMID: 27429164

Neuron-Targeted Nanoparticle for SiRNA Delivery to Traumatic Brain Injuries

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2016 Jul 19
PMID 27429164
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Traumatic brain injuries (TBIs) affect 2.5 million Americans per year, and survivors of TBI can develop long-term impairments in physical, cognitive, and psychosocial functions. Currently, there are no treatments available to stop the long-term effects of TBI. Although the primary injury can only be prevented, there is an opportunity for intervention during the secondary injury, which persists over the course of hours to years after the initial injury. One promising strategy is to modulate destructive pathways using nucleic acid therapeutics, which can downregulate "undruggable" targets considered difficult to inhibit with small molecules; however, the delivery of these materials to the central nervous system is challenging. We engineered a neuron-targeting nanoparticle which can mediate intracellular trafficking of siRNA cargo and achieve silencing of mRNA and protein levels in cultured cells. We hypothesized that, soon after an injury, nanoparticles in the bloodstream may be able to infiltrate brain tissue in the vicinity of areas with a compromised blood brain barrier (BBB). We find that, when administered systemically into animals with brain injuries, neuron-targeted nanoparticles can accumulate into the tissue adjacent to the injured site and downregulate a therapeutic candidate.

Citing Articles

KHSRP-mediated Decay of Axonally Localized Prenyl-Cdc42 mRNA Slows Nerve Regeneration.

Zdradzinski M, Vaughn L, Matoo S, Trumbull K, Loomis A, Thames E bioRxiv. 2025; .

PMID: 39975228 PMC: 11839134. DOI: 10.1101/2025.02.06.636857.


A simple polydopamine-based platform for engineering extracellular vesicles with brain-targeting peptide and imaging probes to improve stroke outcome.

Shi X, Zhang L, Wu S, Zhang C, Mamtilahun M, Li Y J Extracell Vesicles. 2025; 14(1):e70031.

PMID: 39783851 PMC: 11714163. DOI: 10.1002/jev2.70031.


Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.

Soto M, Lewis M, Leal J, Pan Y, Mohanty R, Veyssi A Mol Ther Nucleic Acids. 2024; 35(4):102375.

PMID: 39640013 PMC: 11617931. DOI: 10.1016/j.omtn.2024.102375.


PEGylated Multimeric RNA Nanoparticles for siRNA Delivery in Traumatic Brain Injury.

Han S, Yoo W, Carton O, Joo J, Kwon E Small. 2024; 21(10):e2405806.

PMID: 39498752 PMC: 11899522. DOI: 10.1002/smll.202405806.


Nanocarrier-mediated siRNA delivery: a new approach for the treatment of traumatic brain injury-related Alzheimer's disease.

Jin J, Zhang H, Lu Q, Tian L, Yao S, Lai F Neural Regen Res. 2024; 20(9):2538-2555.

PMID: 39314170 PMC: 11801294. DOI: 10.4103/NRR.NRR-D-24-00303.


References
1.
Schroeder A, Heller D, Winslow M, Dahlman J, Pratt G, Langer R . Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2011; 12(1):39-50. DOI: 10.1038/nrc3180. View

2.
Lin K, Kwon E, Lo J, Bhatia S . Drug-induced amplification of nanoparticle targeting to tumors. Nano Today. 2018; 9(5):550-559. PMC: 5935498. DOI: 10.1016/j.nantod.2014.09.001. View

3.
Hwang D, Son S, Jang J, Youn H, Lee S, Lee D . A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials. 2011; 32(21):4968-75. DOI: 10.1016/j.biomaterials.2011.03.047. View

4.
Baskaya M, Rao A, Dogan A, Donaldson D, Dempsey R . The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats. Neurosci Lett. 1997; 226(1):33-6. DOI: 10.1016/s0304-3940(97)00239-5. View

5.
El Badawy A, Luxton T, Silva R, Scheckel K, Suidan M, Tolaymat T . Impact of environmental conditions (pH, ionic strength, and electrolyte type) on the surface charge and aggregation of silver nanoparticles suspensions. Environ Sci Technol. 2010; 44(4):1260-6. DOI: 10.1021/es902240k. View